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Abstract
Introduction Understanding the balance between the benefits and risks of vaccination is essential to ensure informed and 
adequate public health decision making. Quantitative benefit–risk models (qBRm) represent useful tools to help decision 
makers with supporting benefit–risk assessment throughout the lifecycle of a medical product. However, few initiatives have 
been launched to harmonise qBRm approaches, specifically for vaccines.
Objectives The aim of this paper was to identify publications about qBRm applied to vaccines through a systematic literature 
review, and to describe their characteristics.
Methods Medline, Scopus and Institute for Scientific Information Web of Knowledge databases were searched to identify 
articles in English, published from database inceptions up to December 2019. The search strategy included the combina-
tion of three key concepts: ‘benefit–risk’, ‘modelling’ and ‘vaccines’. Data extracted included the modelling context and 
the methodological approaches used.
Results Of 3172 publications screened, 48 original publications were included. Most of the selected studies were published 
over the past decade and focused on rotavirus (15), dengue (10) and influenza (6) vaccines. The majority (30) of studies 
reported analyses related to high-income countries. The methodology of the studies differed, particularly in modelling tech-
niques, benefit–risk measures, and sensitivity analyses. The present work also pointed out a high level of variability in the 
quality of reporting across studies, with particular regard to input parameters and methodological approaches.
Conclusions This review provides an extensive list of qBRm applied to vaccines. Discrepancies across studies were identified 
during our review. While the number of published qBRm studies is increasing, no reporting guidance for qBRm applied to 
vaccines is currently available. This may affect decision makers’ confidence in the results and their benefit–risk assessment(s); 
therefore, the development of such reporting guidance is highly needed.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4026 4-020-00984 -7) contains 
supplementary material, which is available to authorized users.
 * Hugo Arlegui 
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1 Introduction
Vaccination is one of the most successful public health 
achievements for disease prevention [1]. Compared with 
most other medicines, vaccines have some unique fea-
tures; (i) they can be administered to large populations of 
healthy subjects, including children [2], and (ii) they can 
be introduced by health authorities as mandatory [3]. These 
specificities require vaccines to have a highly favourable 
benefit–risk profile [4]. In practice, this means that the ben-
efits of vaccination need to be compared with its risks, in 
order to ensure informed and adequate public health decision 
making. Benefit–risk assessment (BRA) is the basis of regu-
latory decisions in both pre- and post-marketing review pro-
cesses [5]. Although qualitative judgments have been used 
in BRA of health interventions, quantitative benefit–risk 
models (qBRm) may provide better consistency, transpar-
ency and predictability of decision making [6–8].
qBRm integrate evidence from multiple sources to quan-
tify and put into perspective the benefits and risks of a health 
intervention. They can be simulation models (applying simu-
lation techniques of various complexity degrees to estimate 
final outcomes) or non-simulation models (using a simple 
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Key Points 
Although quantitative benefit–risk models (qBRm) 
represent useful tools to support decision makers in 
assessing the benefits and risks throughout the lifecycle 
of a medical product, few initiatives have been launched 
to harmonise qBRm approaches applied to vaccines.
The aim of the present review is to provide a complete 
list of available studies about qBRm applied to vaccines 
and to describe their characteristics according to the 
modelling context and the methodological approaches 
used.
Discrepancies across studies in terms of quality of 
reporting and methodological approaches used were 
observed in our review. Thus, we advocate for the devel-
opment of an operational checklist for improving the 
reporting in scientific articles.
is lacking. To this end, we developed this first paper (Part 
I) aiming at systematically reviewing publications about 
qBRm applied to vaccines, and to describe their character-
istics. Based on this mapping exercise and in order to ease 
the interpretation of future qBRm, we developed a second 
paper (Part II) that proposes standards in reporting qBRm 
applied to vaccines [26].
2  Materials and Methods
The definitions of technical terminologies (quantitative and 
qualitative BRA, qBRm) used in this article, and adapted 
from the glossary developed by PROTECT [8, 27], are pro-
vided in the Appendix Table 1 (see Electronic Supplemen-
tary Material [ESM]).
2.1  Literature Search and Study Selection
Medline, Scopus and the Institute for Scientific Information 
(ISI) Web of Knowledge databases were searched to identify 
articles published from database inceptions up to 31 Decem-
ber 2019. The search strategy combined three key concepts: 
(i) benefit–risk, (ii) modelling and (iii) vaccines. The search 
was conducted on 13 March 2020 and was limited to articles 
in English (see Appendix Table 2, ESM).
All citations were downloaded and imported in the refer-
ence management software EndNote version X7 (Thomson-
Reuters Corp, New York, NY, USA). Duplicate citations 
were identified and excluded using the reference manage-
ment software and manual title examination. Two reviewers 
(HA and NP) independently screened all titles and abstracts 
using predefined exclusion criteria (see Appendix Table 3, 
ESM). Subsequently, all publications retained after screen-
ing were assessed for eligibility by examining their full text. 
Disagreements between the two reviewers were resolved 
through discussion. A secondary manual search was per-
formed through snowballing the reference lists of the eli-
gible articles to identify additional articles. A grey litera-
ture search was performed through searching major public 
health organisation websites and using targeted search terms 
in Google.
2.2  Data Extraction
The following data were extracted by reviewers: (i) the gen-
eral information including study publication date and the 
funding source; (ii) the modelling context including vac-
cine indication, the geographical location and the income 
level of the countries considered in the analyses according 
to the World Bank classification, the targeted population, the 
alternatives used for comparison with standard vaccination 
and the perspectives from which the intervention’s benefit 
calculation to obtain final outcomes) [8–10]. They have been 
increasingly considered by decision makers (regulatory 
authorities, pharmaceutical companies, payers, guideline 
developers, etc.) to support the BRA of drugs and vaccines 
throughout their lifecycle [11–13]. However, although the 
advantages of using qBRm to weight benefits against risks 
are recognised by some regulatory authorities, formal guide-
lines are currently not available [14–16].
During the last decade, several initiatives have been under-
taken to harmonise qBRm approaches applied to drugs through 
the identification, appraisal and classification of qBRm meth-
ods and the development of recommendations or frameworks 
to perform qBRm; for example, the Benefit–Risk Methodol-
ogy Project driven by the European Medicines Agency (EMA) 
[9, 17], the Pharmacoepidemiological Research on Outcomes 
of Therapeutics (PROTECT) consortium in Europe [8, 10, 
18–21], the Unified Methodologies for Benefit–Risk Assess-
ment (UMBRA) [22] and the International Society for Phar-
macoeconomics and Outcomes Research (ISPOR) Risk–Ben-
efit Management Working Group [23].
Vaccine specificities may require specific modelling 
approaches, like those considering dynamic transmission 
and the occurrence of both individual and indirect protection 
through herd immunity. For this reason, similar initiatives 
aiming at streamlining qBRm approaches applied to vac-
cines have been launched, that is, the Accelerated Devel-
opment of Vaccine benefit–risk Collaboration in Europe 
(ADVANCE) [24] and the Vaccine Monitoring Collabora-
tion for Europe (VAC4EU) [25].
However, to date, a comprehensive review of the litera-
ture about qBRm applied to vaccines, comprising details on 
the modelling context and methodological approaches used, 
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and risk outcomes are evaluated; and (iii) the methodologi-
cal approaches, that is, the modelling techniques, the model 
attributes, the benefit–risk measures, the sensitivity/scenario 
analyses and whether a standardised framework, a tabular 
representation summarising input parameters, discount rates 
and utility or preference information, were used or not. See 
Appendix Table 4 (ESM) for more details and definitions.
The data extraction template was developed based on sim-
ilar initiatives about qBRm applied to drugs, particularly on 
the modelling context [9, 18, 28, 29] and the methodological 
approaches [9, 10, 17, 21, 23], and was adapted to consider 
vaccine specificities (i.e. dynamic modelling technique, herd 
immunity and waning effect attributes) [24, 30, 31].
Two reviewers (HA and KB) independently extracted 
data from the selected articles. Disagreements were resolved 
through discussion. The authors of the papers selected for 
data extraction were not contacted to provide additional 
information.
2.3  Data Extraction
Tables 1 and 2 describe the general information, the mod-
elling context and the methodological approaches of each 
study. Table 3 summarises the distribution of methodologi-
cal approaches depending on the use of a simulation model 
or non-simulation model.
Distribution of the number of publications according to 
the source of funding and the modelling techniques used 
over time is described in Fig. 2 and Appendix Fig. 1 (see 
ESM).
3  Results
3.1  Selection of Studies
The literature search retrieved 4917 potentially relevant 
publications, of which 1745 were duplicates and hence 
excluded. Of the remaining 3172 publications screened, 
3081 were excluded due to lack of relevance, as determined 
by evaluation of their title and abstract. The full texts of the 
remaining 91 publications were extensively evaluated and 
discussed, leading to the exclusion of 52 articles. Reasons 
for exclusion were repetitive data from original studies (2), 
non-relevant publication type (14), non-qBRm studies (35) 
and no access to the full-text article (1). Nine additional 
publications were included through snowballing the refer-
ence lists. A total of 48 publications [32–79] were retained 
for data extraction (Fig. 1). Tables listing the publications 
and reasons for exclusion and inclusion after assessment of 
the eligibility of the full texts are provided in the ESM (See 
Appendix Tables 5 and 6).
3.2  General Information
A temporal trend analysis of the selected articles according 
to their publication date showed that the number of publica-
tions focusing on vaccine qBRm was limited before the year 
2000 and increased from 2008 onwards, with an average of 
three publications per year (Fig. 2). Ten studies disclosed 
funding by pharmaceutical companies.
3.3  Modelling Context of Selected Studies
Most of the vaccines included in the selected publications 
were targeting viruses (40). Two-third of the studies were 
performed for three viruses (rotavirus (15), dengue (10) and 
influenza (6)). By contrast, other indications were only sup-
ported by a single publication (e.g. Human Papillomavirus 
or Hepatitis B virus) (Table 1).
Most countries considered in the analyses were high-
income countries (30) and the majority were located in the 
United States and in Europe (Table 1).
In most studies (45), the targeted population analysed in 
the selected studies was clearly specified and most referred 
to paediatric populations (38). Others focused on the gen-
eral population without any further specification (3) or were 
conducted in several populations (e.g. paediatric and adult 
populations or general and high-risk populations) (4).
Most studies compared standard vaccination versus 
absence of vaccination (30), and only a few compared dif-
ferent vaccines of the same class (3). In some cases (15), the 
vaccine was compared with several alternatives (e.g. stand-
ard vaccination versus absence of vaccination and standard 
vaccination versus vaccination with extended indication).
A large proportion of studies described the perspectives 
at a population level only (40), compared with individual 
(3) or both levels (5).
3.4  Methodological Approaches Used in Selected 
Studies
Few studies (5) used a structured approach or tool that facili-
tates the development of the qBRm (Tables 2 and 3). Among 
them, the multi-criteria decision analysis (MCDA) was the 
main standardised framework used (3) [34, 60, 61].
Studies included in the review used non-simulation 
(16) or simulation models (32) to estimate final outcomes. 
Among the simulation models, the most common types were 
the dynamic model (12), followed by the decision tree (5), 
Markov model (4) and microsimulation (1). Of note, one-
third (10) of the simulation models did not specify the mod-
elling technique used. We did not observe a temporal trend 
of modelling techniques (non-simulation versus simulation) 
(See Appendix Fig. 1 in the ESM).
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Table 1  Characteristics of the general information and the modelling context used in quantitative benefit–risk models applied to vaccines











2018 Yes Rotavirus HIC (UK) Paediatric No vaccination Population
Bollaerts et al. 
(1) [33]
2019 Yes Pertussis HIC (Europe) Paediatric No vaccination Population
Bollaerts et al. 
(2) [34]











Bruun et al. [36] 2019 No Rotavirus HIC (Norway) Paediatric Several alterna-
tives
Population
Carlin et al. [37] 2013 No Rotavirus HIC (Australia) Paediatric No vaccination Population
Cho et al. [38] 2010 No Meningococcal HIC (US) Not specified No vaccination Population
Clark and Cam-
eron [41]
2006 No Tuberculosis HIC (Canada) Paediatric No vaccination Population
Clark et al. [39] 2014 No Rotavirus HIC (England) Paediatric Several alterna-
tives
Population







2016 Yes Dengue virus Worldwide Paediatric No vaccination Population
Coudeville et al. 
[42]
2018 Yes Dengue virus LMIC (Philip-
pines)
Paediatric No vaccination Both
Desai et al. [44] 2013 No Rotavirus HIC (US) Paediatric No vaccination Population
Desai et al. [45] 2012 No Rotavirus LMIC (Latin 
American 
countries)
Paediatric No vaccination Population
Ferguson et al. 
[46]
2016 No Dengue virus Worldwide Paediatric No vaccination Both
Flasche et al. 
[47]
2016 No Dengue virus Worldwide Paediatric No vaccination Population
Hladish et al. 
[48]
2016 No Dengue virus LMIC (Mexico) Paediatric Several alterna-
tives
Population
Kelly et al. [49] 2010 No Influenza HIC (Australia) Paediatric No vaccination Population
Kent [50] 1992 No Influenza HIC (US) Not specified No vaccination Individual
Koplan et al. [51] 1979 No Pertussis HIC (US/West-
ern Europe)
Paediatric Other vaccine(s) Population
Lamrani et al. 
[52]
2017 No Rotavirus HIC (France) Paediatric No vaccination Population
Ledent et al. [54] 2016 Yes Rotavirus HIC (Japan) Paediatric No vaccination Population
Ledent et al. [53] 2018 Yes Rotavirus HIC (France) Paediatric No vaccination Population
Ledogar et al. 
[55]
2009 No Measles LMIC (Pakistan) Paediatric No vaccination Population







2016 No Dengue virus Worldwide Paediatric Several alterna-
tives
Population
Maier et al. [58] 2017 No Dengue virus LMIC (Brazil) Paediatric No vaccination Population
Manissero et al. 
[59]
2008 No Tuberculosis HIC (Europe) Paediatric Several alterna-
tives
Population
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Most of the qBRm included were static (36), determinis-
tic (31), did not consider herd immunity and waning effect 
(35), assumed a closed model (i.e. the model does not allow 
new individual entrances over time) (47) and stayed at an 
aggregate level (i.e. no tracking of individuals’ behaviour) 
(44) (Tables 2 and 3).
Almost two-thirds (29) of the studies used a tabular rep-
resentation to list and summarise all input parameters used 
in the qBRm.
Few studies (5) used discount rates to reduce the value of 
benefit and risk outcomes over time.
Health state preference values (also called utilities) are 
used to represent the strength of individuals’ preferences for 
different health states. In some studies (8), preference elicita-
tion techniques were performed to weight benefit and risk 
outcomes. In these studies, participants were interviewed 
to obtain preference scores by different methods: standard 
gamble (1), time trade-off (1) and the Index of Well-Being 
HBV hepatitis B virus, HIC high-income countries, HPV human papillomavirus, LMIC low/middle-income countries, US United States
a The income level of the countries in the analyses were based on World Bank income groups (LMIC ≤ US$12,235 < HIC) [89]
Table 1  (continued)











2016 Yes HPV HIC (Europe) Paediatric No vaccination Population
Maro et al. [61] 2014 No Influenza HIC (US) Not specified Several alterna-
tives
Population
Meltzer[62] 2003 No Smallpox HIC (US) Several popula-
tions
No vaccination Individual







1991 No Mumps HIC (England/
Wales)
Paediatric Other vaccine(s) Both
Oleksiewicz 
et al. [65]







1989 No Measles HIC (US) Paediatric Several alterna-
tives
Population
Oster et al. [67] 2010 Yes Influenza HIC (US) Paediatric Other vaccine(s) Population





Patel et al. [70] 2011 No Rotavirus LMIC (Brazil/
Mexico)
Paediatric No vaccination Population







2016 No Dengue virus LMIC (Peru) Paediatric No vaccination Population
Phillips et al. 
[72]






2014 No Dengue virus LMIC (Thai-
land)
Paediatric No vaccination Population
Rothberg et al. 
[74]





1976 No Tuberculosis Worldwide Paediatric No vaccination Population
Shim [76] 2019 No Dengue virus LMIC (Mexico) Paediatric No vaccination Population





Yung et al. [78] 2015 No Rotavirus HIC (Singapore) Paediatric No vaccination Population
Zalkind and 
Shachtman [79]
1980 No Influenza HIC (US) Whole popula-
tion
No vaccination Individual
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(1); the other studies (5) referred to an expert panel for elicit-
ing or weighing data.
Regarding the benefit–risk measures, one-third of the 
studies (16) used measures to estimate benefits and risks 
separately (single indices), followed by composite measures 
to integrate benefits and risks (trade-off indices) (13) and the 
remaining ones (19) used both (Tables 2 and 3). The most 
commonly used single indices were the impact numbers 
(34) and the number needed to vaccinate/to harm (NNV/
NNH) (8). Impact numbers measure the number of events 
prevented by and/or cases attributable to vaccination within 
a given population. NNV and NNH provide the number of 
patients who need to be vaccinated for preventing or induc-
ing one case of the event of interest. The most commonly 
used trade-off indices were the benefit–risk difference (or net 
health benefit [NHB]) (18) and the benefit–risk ratio (BRR) 
(13). NHB estimates the difference between the total various 
benefits and the total various risks of a specified vaccination. 
BRR divides a single benefit by a single risk. BRR and NHB 
expressed all outcomes in the same metric.
Almost all included studies (47) used a visual repre-
sentation of their quantitative benefit–risk results, notably 
tables (34), line graphics (23), bar charts (8), scatter plots 
(6), box plots (5) and area graphs (2).
Most studies (44) conducted sensitivity and/or scenario 
analyses including one-way deterministic sensitivity analy-
ses (13), multiple-way deterministic sensitivity analyses (4), 
probabilistic sensitivity analyses (20) and scenario analy-
ses (37) (Tables 2 and 3). Most of the studies using non-
simulation models only reported scenario analyses (12). 
By contrast, most studies with simulation models reported 
sensitivity (deterministic and/or probabilistic) analyses (25).
4  Discussion
To our knowledge, the present study is the first that sys-
tematically reviewed published information about qBRm 
applied to vaccines. This study was not intended to appraise 
the qBRm quality but aimed to build a comprehensive repos-
itory of the available publications about qBRm applied to 
vaccines. The present work is the first of two companion 
papers. Based on this mapping exercise (i.e. Part I), we 
developed a second paper that proposes standards of report-
ing for qBRm applied to vaccines (Part II) [26].
4.1  General Information
Since the late 1990s, the development of qBRm has been 
progressively encouraged by regulatory authorities [14–16, 
80, 81]. Although the first qBRm applied to vaccines iden-
tified in our systematic literature review was published in 
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The number of those developed by pharmaceutical compa-
nies has increased over time. This trend may be explained by 
the recent launch of international consortiums [18, 24, 25] 
facilitating collaboration between public and private partners 
to develop tools for assessing benefit–risk, particularly for 
vaccines.
4.2  Modelling Context
Among the 48 original publications included, the major-
ity targeted the rotavirus, dengue and influenza vaccines. 
The focus on rotavirus vaccines might be explained by their 
association with a transient increased risk of intussusception 
following administration [82]. The high number of publi-
cations about the recent dengue vaccine is likely to be 
caused by the increased risk of ‘secondary-like’ infection 
in populations [83]; in this context, qBRm were performed 
to simulate optimal vaccine strategies according to differ-
ent transmission intensity settings and serological status 
impacts. For influenza vaccines, the variable nature of the 
influenza viruses requiring the undertaking of a new vaccine 
version each fall is a likely explanation [84]. By contrast, 
qBRm were not performed for some vaccines, notably older 
ones, such as those for diphtheria or poliomyelitis, probably 
because the recent adoption of qBRm and the benefit–risk 
balance of older vaccines is no longer questioned.
Table 3  Distribution of the methodological approaches stratified by use of a simulation or non-simulation model
a Some studies can use several measures (among single and trade-off indices)
b Some studies can perform several sensitivity/scenario analyses






Total (N = 48)
n (%)
Standardised framework
 Yes 3 (9%) 2 (13%) 5 (10%)
Model attributes
 Static model as opposed to transmission dynamic model 20 (63%) 16 (100%) 36 (75%)
 No herd immunity effect 21 (66%) 14 (88%) 35 (73%)
 No waning effect 20 (63%) 15 (94%) 35 (73%)
 Closed cohort as opposed to open cohort 31 (97%) 16 (100%) 47 (98%)
 Deterministic model as opposed to stochastic model 15 (47%) 16 (100%) 31 (65%)
 Aggregate model as opposed to individual-based model 28 (88%) 16 (100%) 44 (92%)
Table summarising input parameters
 Yes 22 (69%) 4 (25%) 26 (54%)
Discount rates
 Yes 5 (16%) 0 (0%) 5 (10%)
Utility and preference information
 Yes 6 (19%) 2 (13%) 8 (17%)
Benefit–risk  measuresa
 Singles indices 20 (63%) 15 (94%) 35 (73%)
  Impact number 20 (63%) 14 (88%) 34 (71%)
  Number needed to vaccinate/harm 2 (6%) 6 (38%) 8 (17%)
  Others 2 (6%) 0 (0%) 2 (4%)
 Trade-off indices 26 (81%) 6 (33%) 32 (67%)
  Benefit–risk ratio 10 (31%) 3 (19%) 13 (27%)
  Benefit–risk difference 16 (50%) 2 (13%) 18 (38%)
  Others 2 (6%) 1 (6%) 3 (6%)
 Visual representation used 31 (97%) 16 (100%) 47 (98%)
Sensitivity/scenario  analysesb
 Deterministic sensitivity analyses 12 (38%) 1 (6%) 13 (27%)
  One-way deterministic sensitivity analyses 12 (38%) 1 (6%) 13 (27%)
  Multiple-way deterministic sensitivity analyses 4 (13%) 0 (0%) 4 (8%)
 Probabilistic sensitivity analyses 19 (59%) 1 (6%) 20 (42%)
 Scenario analyses 25 (78%) 12 (75%) 37 (77%)
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Most qBRm targeted high-income countries. Their results 
may thereby not be representative for countries with lower 
income. Estimation of benefits and risks of vaccination 
may indeed vary according to the epidemiology of the dis-
eases and the healthcare system. Those geographical and 
socio-economical specificities should be considered when 
Fig. 1  PRISMA flow diagram
Fig. 2  Distribution of the number of publications according to the source of funding over time
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interpreting qBRm results. Furthermore, the development 
of qBRm applied to vaccines in different settings should be 
encouraged for improving and adapting the decision-making 
process.
4.3  Methodological Approaches
The present work pointed out the high level of variability 
in the quality of reporting across studies. First, it was not 
straightforward to identify input parameters used for each 
qBRm. One-third of the studies did not use a tabular rep-
resentation to list and define all input parameters. Second, 
information on modelling techniques and benefit–risk meas-
ures were not sufficiently outlined, which added complexity 
in extracting the data summarised in Tables 2 and 3. Incom-
plete and inadequate qBRm reporting may affect their result 
interpretation, their reproducibility, and potentially, any 
related decision-making process (e.g. the approval and/or 
recommendation of a new vaccine or its indications). Devel-
oping reporting guidance is therefore the key to helping 
ensure transparency and reproducibility of qBRm applied 
to vaccines, but is currently lacking.
One of the main findings of this review was the heteroge-
neity observed across studies in terms of their methodology. 
First, two-thirds of the studies used simulation models to 
estimate final outcomes. Among the simulation models, the 
number of static and dynamic models was similar. Dynamic 
models are particularly useful when targeting infectious dis-
eases because they allow taking into account the evolution of 
certain factors that modulate the risk of infection over time, 
such as immunity [85]. Of note, except for two publications, 
all dynamic transmission models were performed for the 
dengue vaccine. The low number of transmission dynamic 
models used for other vaccines may be related to their high 
level of complexity, requiring more advanced programming 
skills [31]. Second, a few studies incorporated health state 
preference values, offering the advantage that it represents 
the strength of individuals’ preferences for different health 
states, thereby moving beyond the narrow biomedical model 
for evaluative research [86]. Various techniques were used 
to obtain health state preference value. Third, benefit–risk 
measures considered also differed from one study to another. 
Single, trade-off and both indices were each used in one-
third of the selected studies. Single indices are valued for 
their intuitive interpretation by clinicians and decision mak-
ers. Conversely, by using a commensurable score, trade-off 
indices confer the advantage of providing a straightforward 
comparison of benefit and risk outcomes, thereby facilitat-
ing the BRA. Nevertheless, trade-off indices may be less 
intuitive and can only be performed when both benefit and 
risk outcomes use the same metric. Fourth, almost all stud-
ies performed uncertainty analyses by varying one or more 
key parameter values, using various techniques such as 
scenario (18), sensitivity (7) and both (18). The questions 
on benefit–risk decision are heterogeneous, due to differ-
ences like targeted population, benefit and risk outcomes 
and importance of indirect effects. Thus, there is no one-
size-fits-all approach, as proved by the high level of meth-
odological heterogeneity among the selected publications. 
This observation highlights the richness of methodological 
approaches available to perform qBRm applied to vaccines; 
each of them with their own strengths and weaknesses. 
The choice of methodological approaches depends on sev-
eral considerations like the analyst’s technical skills, the 
required model complexity, the question at hand and the 
nature of the decision matter, the natural history and features 
of the particular infectious disease and the data available 
to parameterise and calibrate the model [87, 88]. Conse-
quently, it is crucial to develop methodological guidance to 
help researchers use the best methodological approach suited 
to specific situations. Furthermore, the variety of methodo-
logical approaches available reinforces the need for specific 
standards in reporting.
The present review has some limitations. Even though 
we aimed to be comprehensive, we cannot guarantee that all 
relevant studies were identified, mainly because there are no 
specific keywords for qBRm. Furthermore, grey literature 
is not identifiable through conventional methods of biblio-
graphic search, and consequently, some relevant websites or 
other source(s) of information might be missing. However, 
various search strategies were tested before selecting the 
one that allowed us to retrieve the largest number of rel-
evant publications, while keeping the number of articles to 
be reviewed within acceptable limits.
5  Conclusion
This study is the first that systematically reviewed published 
information about qBRm applied to vaccines. Our findings 
showed (i) large differences in terms of methodology used 
to perform qBRm applied to vaccines and (ii) a noticeable 
heterogeneity across studies in terms of quality of reporting. 
Since the number of published qBRm studies is increas-
ing over time and given that paucity of formal guidance for 
qBRm applied to vaccines may affect the confidence in these 
models’ results, the development of specific standards of 
reporting should help to ensure the transparency and repro-
ducibility. Part II of this series of companion papers pro-
poses an operational checklist aimed to improve the report-
ing of qBRm applied to vaccines in scientific articles.
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